A new trading day began on Friday, with MaxCyte Inc (NASDAQ: MXCT) stock price down -6.96% from the previous day of trading, before settling in for the closing price of $1.58. MXCT’s price has ranged from $1.26 to $5.20 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -11.37%. Meanwhile, its annual earnings per share averaged 0.43%. With a float of $98.26 million, this company’s outstanding shares have now reached $106.64 million.
MaxCyte Inc (MXCT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of MaxCyte Inc is 7.89%, while institutional ownership is 70.68%. The most recent insider transaction that took place on Jun 25 ’25, was worth 22,378. In this transaction Director of this company sold 10,684 shares at a rate of $2.09, taking the stock ownership to the 39,893 shares. Before that another transaction happened on Aug 13 ’25, when Company’s CHIEF FINANCIAL OFFICER bought 50,000 for $1.29, making the entire transaction worth $64,500. This insider now owns 161,811 shares in total.
MaxCyte Inc (MXCT) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.1 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.63% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Here are MaxCyte Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Looking closely at MaxCyte Inc (NASDAQ: MXCT), its last 5-days average volume was 2.97 million, which is a jump from its year-to-date volume of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 23.43%.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 18.92%, which indicates a significant increase from 12.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1248 in the past 14 days, which was higher than the 0.1079 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6108, while its 200-day Moving Average is $2.1291. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $1.6067. Second resistance stands at $1.7433. The third major resistance level sits at $1.8367. If the price goes on to break the first support level at $1.3767, it is likely to go to the next support level at $1.2833. Should the price break the second support level, the third support level stands at $1.1467.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
With a market capitalization of 156.81 million, the company has a total of 106,674K Shares Outstanding. Currently, annual sales are 38,630 K while annual income is -41,060 K. The company’s previous quarter sales were 6,830 K while its latest quarter income was -12,420 K.
